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1. Introduction 
Alzheimer’s disease is not only the most frequent cause of dementia that takes its toll on the 
elder population, but it is also the disorder for which, despite the complex research 
performed, a certain diagnosis may only be performed through anatomic-pathologic 
examination. 
Alzheimer’s disease is a neurodegenerative disease whose defining anatomic-pathologic 
trait is the deposit of amyloid plaques at the level of certain areas of the brain, the presence 
of fibrillary degeneration in the neurons and vascular changes with an amyloid deposit, all 
of which result in the impressive reduction of the cerebral mass noticed in the final stages of 
the condition. 
Studies of over 30 years have established that olfaction is impaired in AD, however not 
invariably.  
As early as 1987, Rezek described olfactory deficit as a neurological sign in Alzheimer 
dementia. Recent research has started to clear up potential mechanisms of olfactory loss in 
Alzheimer’s disease. 
Alzheimer disease has a selective vulnerability of the cerebral structures to the pathologic 
process, inducing a distinctive lesion pattern with a slow evolution in time and that is 
constantly invariable in the study cases. It begins in the transtentorial region and it then 
expands to the cortical and subcortical components of the limbic system and it may include 
the association areas of the neocortex. The pathologic process may be progressive, 
containing 6 stages. In stages 1-2, the pathologic process takes place at the level of the 
anteromedial temporal lobe mesocortex, the entorhinal allocortex and the horn of Ammon. 
Such structures are not only related to memory and learning, but also to the olfactory 
system. Therefore, stage 1-2, considered “clinically silent”, includes a series of non-cognitive 
clinical changes that are essential for the timely diagnosis of the disease, including olfactory 
changes. 
The deficit of the olfactory system in Alzheimer’s disease, as early as its incipient stages, is 
currently a generally recognized fact. The correlation between olfaction and Alzheimer’s 
disease is particularly exciting, with important diagnosis practical implications. 
The olfactory system is a unique system of the human brain; it belongs to archaic structures, 
its anatomic route is distinguished by the fact that it is the only means of sense that 
approaches the brain directly, it is the only sensatory system with direct cortical projections, 
without a thalamic relay, it is the only part of the brain where neurogenesis persists, it has a 
special reaction to the aging process, it plays an essential role in behavior (food behavior, 
orientation and sexual behavior) and it influences memory, as there is also a smell memory.    
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2. Olfaction and memory - investigating the olfactory system 
The olfactory primary cortex is the place processing the olfactory information at the highest 
level and it is directly related to the amygdale and the hippocampus. The amygdale plays an 
important role in the formation and modulation of emotions, as well as in emotional 
memory. The hippocampus is involved in memory processes, especially in working memory 
and in short term memory. Olfaction is the sensory manner that is closest to the limbic 
system, including both the amygdale and the hippocampus, and that is responsible for 
emotions and memory. Olfaction and memory are so infused that they allow us to make 
connections with certain experiences we have been subject to (the capacity of a smell to 
evoke memories). 
This is probably why memories evoked by smells are particularly strong at an emotional level. 
An individual olfactory stimulus may trigger different perceptions that depend on previous 
experiences and olfactory learning. Recent studies of cerebral imagery have indicated 
changes based on experience of the piriform cortex. (Li et al 2008) The anatomic bases of 
olfactory learning in such cerebral regions may involve a complex system of association 
fibers connecting neurons from the same areas or different cortical areas and whose synapse 
power may be changed by olfactory experience. (Wilson et al 2004) Olfactory learning may 
amplify the discrimination of smells and it may be important in survival. In humans, 
changes in the neuronal cortical activity determined by olfactory learning are correlated 
with the improvement in the discrimination of similar smells. (Li et al 2008)  
Olfaction has often been involved in learning processes. 
Since the olfaction system is connected to the limbic system, which explained earlier is 
responsible for the storing and creation of memories, this leads us to the conclusion that 
each receptor will recognize a specific scent if it had previously been exposed to it, basically 
creating memories. 
It can also be significant that demyelinized olfactory fibers make olfaction the sense with the 
slowest driving. Not only does it require a longer time for the brain to perform the olfactory 
perception, but the sensation of a smell also persists more than, for example, visual or auditory 
sensation. Moreover, the fact that olfactory receptors are the only sensory receptors that are 
directly exposed to the environment may explain the relation between olfaction and memory.  
Despite the fact that initial studies have not recognized it, there is also a short term olfactory 
memory. 
White and Treisman have suggested that olfactory memory occurs due to the fact that 
humans assign verbal meanings to olfactory stimuli. The memory of smells is improved by 
familiarity and the capacity of identification. 
Episodic information is an essential constituent of olfactory memory, comparative with the 
form and structure of the visual and auditory memory systems. All smells are encoded as 
"items" in the piriform cortex. The perception of smells is totally dependant on the integrity 
of this memory system and the loss thereof leads to the dysfunction of perception. 
Neuro-transmitters in the olfactory system are responsible for the neuronal plasticity and 
behavioral changes. Noradrenaline and acecoline influence both implicit and explicit memory.    
Implicit memory 
It does not imply the conscious memory of the initial exposure to smell. The proof of the 
implicit memory formation of smells is given by habit, sensitization, perceptual learning and 
classic conditioning tests. Olfaction includes a strong tendency of habit. 
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Habit  
It involves the decrease of the level of attention and response to a stimulus that is no longer 
perceived as new. It refers to decreasing the levels of response to a smell due to extended 
exposure. It involves the adaptation of cells in the olfactory system. It concerns both 
receptors, mitral cells of the BO, and cells in the piriform cortex with a rapid adaptation rate. 
Noradrenaline is deemed to have an effect in the operation of mitral cells and in increasing 
the response level thereof. 
Explicit memory  
Is a phenomenon encountered exclusively in humans. It concerns the assigning of 
associative meanings to different smells. The testing thereof uses the identification and 
recognition of smells. 
In humans it was noticed that the Korsakoff syndrome, with an important memory 
dysfunction, the memory of smells is less impaired than other types of memory, thus 
suggesting a separate mechanism than other types of memory. 
The testing of the olfactory sense is relatively complex and difficult at the same time. An 
attempt is made to asses the capacity to detect, identify, recognize and differentiate smells. 
- The odor detection threshold is the lowest concentration of a certain odor compound 
that is perceivable by the human sense of smell. The threshold of a chemical compound 
is determined in part by its shape, polarity, partial charges and molecular mass 
- The identification of smells is a semantic task, referring to general individual 
knowledge or to experience with a specific smell. (Schab 1999, Tulving 1993) The 
identification of smells is related to semantic memory, as there is a relation between 
smells and the name thereof. No significant relation was ascertained with intelligence, 
short term memory and episodic memory. 
The episodic memory of smells is mediated by semantic factors (familiarity and 
identification of smells); the difficulty in the identification of common smells is based on 
deficits of the smell memory. 
It is worth noting that it is the strong influence of the perception of intensity on the 
identification of smells. Individual variations in the perception of intensity are a major 
element for successful identification and it must be considered in the study assessing 
identification. 
Odor identification ability is sensitive to prefrontal lobe dysfunction.      
The objectification of smells by the identification of the name makes the subtle connection 
between memory and the environment. 
Olsson (1999) suggested that the identification of smells interferes with memory. The 
identification of smells has a positive effect on the recognition of smells and it deems the 
name of smells to be a high level of cognition. 
There is also a peri-semantic implicit episodic memory of smells and this spontaneous smell 
memory remembers especially connections with experienced situations. 
Identification provides the individual with a secondary memory channel, however, the 
question remains if this is for smell itself. 
Once identified, the name is remembered and the memory of this name is reactivated when 
the smell is identified again. 
In order to test whether smell can be identified without verbal mediation, Moller carried out 
an experiment of incidental versus intentional learning recognition with unusual smells, 
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using young and old subjects. In incidental learning, the elderly proved more successful; in 
intentional learning, the young proved better, as they had fewer false alarms and because 
they did not use verbal mediation and not because of the deterioration of their working 
memory. 
If smell memory operates independently from its name, it is mainly tuned at detecting 
changes. 
- Smell recognition is a simple method of checking olfactory memory that does  
not involve language. It only requires that the subject establish, after a period of latency, 
if the substance it smells is the same as that which was provided for it to smell  
before. 
3. Examination of olfaction 
Ideal examination is carried out for each nostril separately. Starting with the asymmetry of 
neuropathologic changes, there is a functional asymmetry in olfactory performances. 
Apparently, in order to diagnose the difference of the olfactory identification capacity and of 
olfactory memory between subjects with MCI and AD, it is useful to test unirinal smell. The 
testing of performances it carried out by considering the affected nostril; a difference may be 
noticed between patients with MCI and AD. If the assessment is made by considering the 
healthy nostril (the olfaction of the two nostrils), the differences between MCI and 
Alzheimer’s disease are no longer present. (Bacher-Fuchs, Moss, 2010). 
Olfactory tests: 
It is necessary for the battery of tested smells to reduce errors and to be adapted at a 
multicultural and ethnic level. It should consider all causes that may lead to the dysfunction 
of the olfactory sense, paying great care to pathological history, associated disorders, the 
therapy the patient is subject to, the pollution it was exposed to (job), etc. 
They must be supplemented and correlated with other factors involved in AD, as well as 
with other situations that may prevent the cognitive function. 
The used tests are: 
1. UPSIT - The University of Pennsylvania Smell Identification Test, “a scratch and sniff 
odor identification test”, including: 
- tests for odor threshold (n butanol testing by means of a single staircase) 
- odor discrimination (16 pairs of odorants, triple forced choice) 
- odor identification (16 common odorants, multiple forced choice from four verbal 
items per test) 
2. “Sniffin’ sticks” - pen like odor dispersing devices which include tests for odor 
identification, discrimination and thresholds 
3. CCCRC (Connecticut Chemosensory Clinical Research Center Test) - a combined odor 
identification and odor threshold test. 
Specialized testing may include EEG derived measured such as the recording of olfactory 
event-related potentials.   
4. Olfaction and aging  
Aging also leads to the decrease of all senses: sight, hearing, tactile, including taste and smell. 
There is a reverse proportionality between age and olfactory sensibility. 
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Olfactory senescence begins at 36 for both genders, and it accelerates with aging, impairing 
pleasant smells. Despite the fact that it is of lower interest for the patient compared to, for 
example, the loss of sight or of hearing, the loss of smell is frequent and often 
unacknowledged. Patients with congenital anosmia are diagnosed with it at about 10 years 
old. 
It was reported that over 75% of the population over 80 years old has a tendency towards 
major olfactory dysfunction, as olfaction decreases considerably after the 7th decade. A more 
recent study has indicated that 62.5% of people between the ages of 80 and 97 are subject to 
olfactory dysfunction. 
Aging is also accompanied by the decrease in the capacity to identify smells and of 
discrimination. 
The loss of olfactory acuteness in elders may be caused by changes in the anatomy of the 
involved structures, the action of environmental factors, medication. Apparently, the main 
causes are: chronic illness, medication, dental and sinus problems. 
Medical causes affecting smell: 
i. Neurological: - Bell’s paralysis  
- chorda tympani dysfunction  
- epilepsy  
- cranial trauma 
- Korsakoff’s syndrome 
- multiple sclerosis 
- Parkinson’s disease 
- tumors 
ii. Nutritional:  
- cancer 
- renal chronic illness 
- liver disease 
- vitamin PP deficit 
- vitamin B12 deficit 
iii. Endocrinous: 
- corticoadrenal insufficiency  
- congenital adrenal hypoplasia 
- panhypopituitarism (Simon’s disease) 
- diabetes mellitus 
- hypothyroidism  
- Kallman’s syndrome 
- McCune–Albright syndrome 
- Turner syndrome 
iv. Local: 
- sinusitis, rhinitis, polyposis 
- asthma 
- xerostomic conditions, including the Sjogren’s syndrome 
v. Viral: 
- acute viral hepatitis 
- flu-like infections 
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However, the studies have indicated that a series of disorders in elders do not impair 
olfaction, such as arterial hypertension and heart diseases. 
The decrease of the olfactory sense in elders may occur by the alternation in the distribution, 
density, functionality of specific receptor proteins, of ionic channels or of signaling 
molecules affecting the ability of the neurons in the olfactory path to signal and process the 
odoriferous information. 
The mechanisms leading to the decrease of the olfactory sense in high age are: the decrease 
of neurogenesis, the decrease in the number of synapses,  a decrease of the total synaptic 
density in the glomerular layer, (STABLE TUBULE ONLY POLYPEPTIDE  could be 
responsible for this phenomenon), the change of growth factors (TGF – alpha, FGF2, BMPs, 
TGF-beta, EGF, BDNF) ,the decrease in the number of nerve terminations at the level of the 
nasal mucous, the decrease in the quantity of mucus at the level of the nasal mucous, 
respectively of the olfactory epithelium, the decrease of neurotransmitters.  
Anatomic changes consist of decreasing the number of olfactory receptors and fibers in the 
olfactory bulb. Losses in the olfactory bulb may be secondary to the reduction of neurons in 
the nasal mucous. Olfactory receptors die through an apoptosis process. The decrease in 
regeneration with age leads to reducing the surface of the olfactory epithelium. This is also 
accompanied by an increase in the death rate of receptors. 
In some cases, olfactory loss occurs due to bone growth and the consequent reduction of the 
cribriform lamella orifices of the ethmoid bone with microlesions of the nerve fillets when 
crossing this structure.  
Functional imagery studies have proved that the activity of the piriform/amygdaliane region 
and of the orbitofrontal cortex is reduced in elder patients exposed to olfactory stimuli. 
Moreover, it was noticed that areas of the cerebellum are activated by olfactory stimuli: the 
upper and inferior semilunar lobe, the posterior quadrangular lobe. In elders, olfactory 
stimulation leads to a higher activation of the cerebellum, suggesting a high response to 
attention requests or a compensating mechanism. 
Age-related deficits concern both the recognition of smells and the identification of smells, 
which may be attributed to cognitive limitation. 
The reduction of the olfactory sense has major consequences of the state of health and on the 
security of the respective patient: hyposmia is inseparably related to the altering of taste, 
leading to inappetence, the decrease of food intake, weight loss, malnourishment, reduction 
of immunity, the deterioration of the state of health. The altering of taste leads to the loss of 
the please of eating, as the patient is deprived of the ability to savor a meal, which may lead 
to depression. As taste is altered, the patient has the tendency to have a high intake of salt 
and sugar which may lead to the aggravation of cardio-vascular diseases or, respectively, to 
diabetes. 
The reduction of the olfactory sense may lead to anxiety, the tendency of isolation. The 
altering of the perception of smell related to one’s own body may lead to the decrease in the 
degree of personal hygiene, with consequent social implications. 
The security of the life of patients with hyposmia is affected by the possibility of ingesting 
altered food, gas intoxication, etc.  
Physical health, financial security, profession, partnership, friendship, emotional stability, 
free time are severely affected by the loss of olfaction. 
The treatment of hyposmia generally has relatively modest results. Treatment may include 
the intake of zinc, vasodilatation substances such as pentoxifylline, as well as of vitamin A, 
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alpha-lipoic acid and NMDA receptor antagonists such as caroverine. Aside from such 
substances, the use of flavoring agents improves taste changes. Studies have indicated that 
the use of food supplements such as flavors leads to the increase of salivary Ig A, the 
increase in the number of T and B cells. 
5. MCI and olfaction 
The assessment of the olfactory function may be a method that is worth trying in order to 
identify patients with memory deficits. Identification performances were studied by using 
MCI. Comparing normal elder subjects with an MCI group, where the identification and the 
remembering of smells were studied, noticed that MCI subjects had significantly lower 
results in their tests, however, the performance in the assessment of smells was less affected 
than the cognitive assessment. 
Moreover, after monitoring elder patients in time (5 years), who did not initially have 
cognitive dysfunctions, where the capacity of olfactory identification was also determined, it 
was ascertained that for those who have developed MCI, the olfactory identification score 
had a predictive value. Respectively, an olfactory score increased the risk of MCI by 50%. 
The results were not changed by the cognitive level in the presence of smoking. The 
reduction of olfaction was associated with a lower basic cognitive level and with a faster 
decline of episodic, semantic memory and of the perceptual speed. Therefore, in elders with 
no manifest cognitive disorder, the difficulty in identifying smells plays the role of 
prediction in the MCI development. 
An important study has monitored 471 elder patients that were not subject to dementia or to 
cognitive disorder, for 5 years (Wilson-Olfactory impairment in presymptomatic 
Alzheimer’s disease), for whom the capacity to identify familiar smells was initially 
assessed, by using the Brief Smell Identification Test, and they well clinically assessed 
annually and they were subject to cerebral anatomo-pathologic examination after their 
death. Moreover, the presence of the APOE epsilon 4 allele was determined. Low BSIT 
scores were associated with a faster decline of episodic memory, with a high risk of 
developing MCI. People who have deceased without a cognitive deficit and with lower BSIT 
scores were associated with a high level of the Alzheimer disease pathology, particularly 
with fibrillary degenerations in the central olfactory regions, especially in the entorhinal 
cortex and the horn of Ammon.  
Such analyses suggest that in an elder population without clinical manifestations of 
Alzheimer’s disease or MCI, the olfactory dysfunction is correlated both with the level of the 
Alzheimer’s disease pathology in the brain and with the risk of the subsequent development 
of prodromal signs of the Alzheimer’s disease symptoms as MCI and of the episodic 
memory decline. Therefore, olfactory manifestations may precede cognitive disorders in 
Alzheimer’s disease with a substantial amount of time. 
Furthermore, decline also occurs with age in other sensory systems in association with 
cognitive decline. As the entorhinal cortex processes multiple sensory impulses, it is possible 
that olfaction may also be accompanied by subtle changes in other sensory functions. 
Therefore, the olfactory deficit occurs both in patients with symptoms of Alzheimer’s 
disease, which was long proven, and in MCI patients or in carriers of the epsilon 4 allele, a 
well established risk factor for Alzheimer’s disease. The respective analysis indicates that 
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the association between the olfactory dysfunction and the pathological changes specific to 
Alzheimer’s disease may also occur in asymptomatic elders.         
Another study has proven that in elders, the presence of APOE is associated with a high risk 
of MCI and a fast cognitive decline. It was also indicated that hyposmia associated with 
APOE has a 5 times higher risk of developing Alzheimer dementia than the general 
population. 
The preliminary data of a study indicates the fact that MCI patients not only have an 
olfactory dysfunction compared to healthy persons, that progresses in time, but that those 
who are not aware of the decline of their olfactory sensibility, suffering from amnestic MCI, 
will develop the criteria for the diagnosis of Alzheimer’s disease in the near future.   
6. Alzheimer's disease and olfaction 
Despite all the research carried out so far, it is still not known why the loss of olfaction 
occurs in victims of Alzheimer’s disease. What is known is that the loss of olfaction is 
current. Ansomia and Alzheimer’s disease go hand in hand. Anosmia was currently studied 
as a potential diagnosis instrument for Alzheimer’s disease. 
In 1994, Solomon examined the first cranial nerve in patients with Alzheimer’s disease. He 
noticed that 90% of the patients had different degrees of anosmia. 
Another experiment compared the olfactory capacity of 80 normal elders with that of 80 elders 
suffering from Alzheimer’s disease, and the latter had a significantly lower olfactory capacity. 
An attempt was even made to quantify the difference of olfactory capacity. Respectively, the 
study performed by Nordin in 1995 proved that 74% patients with Alzheimer’s disease had 
a satisfactory olfaction only after smelling a sample with a concentration that was 9 times 
higher than the initial one, which 77% of the normal elders managed to identify. The same 
study also indicated that patients with Alzheimer’s disease were not aware of the debut of 
their anosmia, nor of the severity of their impairment which is why they did not 
acknowledge the loss of their olfactory sense. 
The amyloid deposit-olfactory impairment relation was proved by Zucco in 1994 in his 
study on patients suffering from Down’s syndrome. It is known that due to the trisomy of 
the chromosome 21 they carry, they have an overexpression of the genes of this 
chromosome, including that of the amyloid precursor protein. Starting with the age of 40, 
they indicate deposits of amyloid plaques at a cerebral level, without however necessarily 
developing it. The risk of developing dementia in a patient suffering from Down syndrome 
is higher in persons with a family history of Alzheimer’s disease, while others have the same 
risk as the general population. With age, patients with Down syndrome are also subject to 
an increase in the rate of Alzheimer’s disease, so that, at 60 years old, 50-70% have 
Alzheimer's disease. Moreover, Alzheimer’s disease has an earlier debut in patients with 
Down syndrome.   
The decrease of the olfactory capacity was also noticed in adults with Down syndrome, 
many of which have a cerebral pathology that is analogue with Alzheimer’s disease. 
The question that was raised next was if adolescents suffering from Down syndrome and 
that were not subject to clear neuropathologic changes similar to Alzheimer’s disease will 
develop an olfactory dysfunction. 
The olfactory sense (the capacity of identification and discrimination) was tested for 20 
teenagers suffering from Down syndrome (13.8 years average age), and the results were 
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compared with 20 patients with Down syndrome who were mentally retarded and 20 
patients with Down syndrome who were not retarded. There were no differences between 
the three groups. 
Another study tested the olfactory sense for 14 young people (20 - 31 years) and 14 adults 
(32 - 54 years) with Down syndrome. The scores were definitely lower in the older group. 
(Amyloid plaques were emphasized together with neurofibrillary degeneration in the 
olfactory mucous).  
Such corroborated studies suggest that the olfactory impairments correlated with Down 
syndrome only occur in elders, when the pathology similar to Alzheimer’s disease is 
present. 
In MCI, the decrease in olfactory identification may be a marker for early Alzheimer’s 
disease, and the Apo E genotype may be a part of the olfactory decline base. 
In his study, Devanand proved that in patients with MCI, low base olfactory identification 
scores predict the diagnosis of Alzheimer’s disease during monitoring. However, the MMSE 
should be considered, together with whether the patient is aware of the olfactory deficit or 
not. Devanand has indicated an association of olfactory and neuropsychological tests with 
an MRI examination for the cerebral volume (entorhinal cortex and horn of Ammon), the 
sensibility of predicting the MCI conversion to AD increases. Such studies have suggested 
that olfactory dysfunction may be a potential useful biomarker in estimating the debut and 
the progression of the disease. 
The power of prediction increases if it is associated with the lack of awareness of the 
olfactory deficit. Low olfactory scores associated with the subjective reporting of the lack of 
olfactory problems are a stronger prediction factor. The correlation between being non-
critical towards olfactory issues and the development of Alzheimer’s disease is important as 
the awareness of the loss of olfactory sense may also be located in the medial temporal lobe 
structures, known to be impaired in the preclinical stages of the disease and associated with 
attention deficits.  
Olfaction was studied (detection, quality of dissemination and identification) together with 
cognition (attention, rationale, memory, name, fluency) in patients with Alzheimer's disease, 
MCI and normal elders. 
Patients with MCI had their olfactory sensibility and identification diminished, while 
discrimination was considered to be under normal limits. 
Alzheimer’s disease impairs all three areas, more than in MCI. It was noticed that the 
performances in the identification and discrimination of smells is correlated better than the 
detection with neuropsychological tests. Therefore, the deficits in detection and 
identification occur early in Alzheimer’s disease, prior to the development of the clinical 
symptoms, and it progresses with the evolution of the disease. High detection thresholds 
together with the impairment of identification may be an early indicator of Alzheimer's 
disease. 
Electrophysiological - olfactory evoked potential studies have confirmed the olfactory 
dysfunction both in patients suffering from Alzheimer’s disease and in the preclinical MCI 
stage. 
In Alzheimer’s disease, the olfactory dysfunction progresses together with the disease and it 
is correlated with its severity.  More advanced stages also register the impairment of 
olfactory discrimination. 
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1996 meta-analyses were performed on 43 olfactory perception and AD studies, and 
significant deficits were noticed in the olfactory detection threshold, the olfactory 
identification and olfactory recognition in confirmed or potential AD cases compared to the 
case-controls of the same age. Such deficits were correlated with genetic factors associated 
with a high risk for AD. 
Gilbert and Murphy have proved that even one or two copies of the APOE allele e4 have a 
significant deficit in smell recognition compared to patients who do not have this allele. The 
authors have indicated that the deficit only applies to olfaction and not to visual stimuli. 
7. The theoryes of olfactory impairment in Alzheimer's disease 
In terms of olfactory impairment in Alzheimer's disease, two theories were raised: the 
olfactory vector theory and the degenerative theory. 
The olfactory vector theory 
In 1985, Pearson et al suggested that in terms of the impairment of the olfactory system in 
striking contrast to the minimal changes of other cerebral areas, it is possible that the 
olfactory system is the gateway for the agents triggering the disease. Therefore, the loss of 
smell may be a consequence of virus access or the access of toxins from the nose to the brain 
via the olfactory path.  
This theory is supported by the following:  
1. In the intranasal instillation of virus or toxins, they can enter the brain by the active 
transport of olfactory cells and it induces the alteration of olfactory structures (Stroop, 
1995) 
2. Studies suggesting histopathologic changes occur in the olfactory epithelium in patients 
with Alzheimer’s disease (Jafek et al, 1992) 
Amyloidal plaques and degeneracy are preferentially located in the limbic system receiving 
fibers directly from the olfactory bulb, including the anterior olfactory nucleus, uncus and 
the medial amygdaline nucleus. (Pearson et al, 1985) 
Secondary degeneration theory  
It postulates that the loss of olfaction is determined by retrograde secondary degeneration. 
A version postulates that limbic structures are particularly susceptible to alteration in the 
processes of Alzheimer’s disease. 
Potential arguments are: 
1. Patients with Alzheimer’s disease have a reverse correlation between the UPSIT scores 
and the metabolic activity in the anterior portion of the medial temporal cortex 
measured by PET (Buchsbaum et al, 1989) 
2. The association between low olfactory scores and the number of hippocampal lesions in 
patients with Alzheimer’s disease (Serby et al, 1992) 
3. Mice which have recently become anosmic do not have a learning deficit, unlike those 
in which anosmia was induced earlier (Kurtz et al, 1989) 
8. The structural bases of the olfactory impairment in Alzheimer disease 
Multiple areas of the brain that are crucial for the normal olfactory function are severely 
impacted by the pathology of Alzheimer’s disease. The olfactory dysfunction of Alzheimer’s 
disease is associated with anatomical-pathological changes specific to the disease both at the 
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level of the olfactory mucous and at the level of the olfactory bulb, of the olfactory tracts and 
of the central region for the projection of olfactory tracts, including regions involved in the 
recognition of smells and memory (entorhinal cortex and the horn of Ammon). 
Deposits of amyloid and neurofibrillary tangles, the two pathological hollmarkes of AD, are 
located differentially by crossing these regions. Few studies have approached the connection 
between the prevalence of these pathologies with the olfactory function. 
A study has suggested that for elders (87 ± 6 years), olfactory loss is determined by the 
loading of neurofibrillary tangles in the central areas processing olfactory information; 
another study has indicated that the severity of the pathology in the olfactory system is 
correlated with the neuropathologic progression of the disease starting from the MCI stage. 
Olfactory identification is impaired early on in Alzheimer’s disease and it may be influenced 
by the cognitive status more than the olfactory acuity or detection that is not alerted until 
late stages. The hyposmia pattern in Alzheimer’s disease suggests that the disease does not 
begin “in the nose”, as was theorized so far. 
Talamo examined the changes in the olfactory neurons in Alzheimer’s disease and he 
indicated that there are histopathologic changes at the level of the olfactory epithelium. 
In 1991, Hyman used neuroanatomic and neurochemical studies to describe the changes at 
the level of the olfactory bulb with deposit of amyloid plaques and neurofibrillary tangles 
with degenerations of other areas: the anterior olfactory nucleus, the olfactory tubercle, 
uncus and subiculum. 
A 1993 study indicated a less severe impairment in Alzheimer’s disease of the olfactory tract 
and bulb in Alzheimer’s disease than in the central part of the olfactory system. 
Immunohistochemical determinations in the olfactory epithelium for the polyclonal protein, 
for amyloid plaques and for ubiquitin have proved the presence thereof in Alzheimer’s 
disease, so that nasal mucous biopsy may be useful. 
It was also noticed that neuroblasts from donors with Alzheimer’s disease have high levels 
of precursor amyloid. 
Imagistic and immunohistochemical studies have proven the correlation between the 
deposit of amyloid plaques and neurofibrillary tangles at the level of the olfactory bulb with 
those at the level of the cortex. 
The study of Wilson and his collaborators, performed in 2007, indicated that the difficulty in 
identifying familiar smells at a high age is partially due to the neurofibrillary pathological 
accumulation in the central olfactory regions, respectively in the entorhinal cortex and the 
CA1/subiculum area in the horn of Ammon, as the density of degeneracy is inversely 
proportional with the olfactory identification. 
In 2009, Thomann carried out MRI studies to indicate the reduction in the sizes of the 
olfactory bulb and tract in the early stage of Alzheimer’s disease. 
An MRI study also described the decrease in the volume of the left horn of Ammon in 
Alzheimer’s disease, reflected in the reduction of olfactory identification performances. 
Experiments carried out on rodents with AD have provided evidence that both the 
neurofibrillary tangles and the beta-amyloid lead to olfactory loss. For example, a recent study 
carried out on a transgenic mouse with the overexpression of the human amyloid beta protein 
precursor indicated that such mice have an age-dependent olfactory dysfunction compared to 
the control group of the same age. Such olfactory deficits include the abnormal investigation of 
smells, olfactory habit (short term memory) and olfactory discrimination. Furthermore, such 
behaviors are correlated with the spatial-temporal deposit of the fibrillary and/or non-
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fibrillary beta-amyloid. It is worth mentioning that the amyloid deposit first occurs in the 
olfactory bulb, followed by the deposit in the olfactory cortex and horn of Ammon.Such data 
suggest that the beta-amyloid deposit in the olfactory bulb and in the olfactory cortical areas 
may contribute to olfactory loss in early and, respectively, late stages. 
 
 
Fig. 1. Anatomical changes of the olfactory pathways in AD 
9. Olfactory sense and other neurodegenerative disease 
The decrease of the olfactory sense is also associated with other neurodegenerative diseases: 
Parkinson’s disease and Lewy corpuscles dementia, 
Olfactory impairments in Alzheimer’s disease and Parkinson’s disease are initially similar, 
and they are later on set apart in terms of quality. In Parkison’s disease, cerebral lesions are 
rarer and the olfactory impairment is more stable. However, it is worth noting that in initial 
studies, the extent of the olfactory changes in Parkinson’s disease is the same as that in 
Alzheimer's disease. 
During the post-mortem examination, patients suffering from anosmia dementia seem more 
likely to have Lewy body dementia. 
Progressive supranuclear palsy -In this disease, the olfactory function is relatively intact, 
with no significant differences between the olfactory scores of such patients compared to the 
case-controls. 
Multiple system atrophy- They have lower olfactory scores than the case-controls, however 
they are better than patients with Parkinson’s disease (Wenning et al, 1993). The olfactory 
impairment has no correlation with the disability scores, and the pathological changes are 
more expanded than in Alzheimer’s disease. 
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In Huntington’s chorea there is impairment in the discrimination and identification of 
smells, however not in the detection thereof. 
10. Olfaction-marker of Alzheimer disease 
A major effort in AD research is directed towards the identification of the markers of the 
disease. Such biomarkers should ideally predict the AD prognosis before the significant 
development of the neuropathology and the consequent loss of the cognitive function. Early 
indicators of the disease are especially important for the implementation of interventions as 
long as the brain is still operating normally. Therefore, the finding of a robust and accurate 
biomarker may be a pivot in the reduction of the AD global impact. 
An overview of the biomarkers’ progression has indicated that the first elements that are 
detected are beta-amyloid, followed by the neurodegeneration and the cognitive markers. 
Despite the fact that they are not normally used, perception impairments may serve as AD 
biomarkers. Perception impairments are common in AD, including the loss of olfaction, of 
visual and hearing abilities. 
The answer to the question on whether olfaction can be used as an AD marker is not simple. 
There are numerous causes of hyposmia. The high prevalence of anosmia in other 
neurodegenerative diseases - PD, DLB, D fronto-temporal indicates that olfaction alone is 
not specific enough as an AD biomarker. Together with other biomarkers, the olfactory 
perception screening may be useful in consolidating the sensitivity and specificity of an AD 
diagnosis, especially due to the fact that it is non-invasive, easy to repeat, it reflects the 
operation of the neuronal circuits impaired in the initial stages of AD, it is not costly and it 
does not require technological equipment. 
Considering the fact that the olfactory deficit is developed with a high frequency in intact 
cognitive subjects, carriers of the e4 allele, olfaction can be a particularly useful and non-
invasive measure in the intervention or prevention of risk trials. 
The testing of the olfactory sense may be useful in differentiating Alzheimer’s disease from 
major depression. 
Anosmia may be a respectable method of diagnosis in Alzheimer’s disease. The careful 
monitoring of the decline of the olfactory sense may indicate the debut of Alzheimer’s 
disease. 
Anosmia may be used as a probable indicator in the diagnosis of Alzheimer’s disease, 
however it cannot be a decisive factor by itself. 
Longitudinal studies during the progression of the disease, correlated with independent 
measurements of the structural and functional deficits in relevant areas of the brain will 
establish the usefulness of olfactory tests. 
The smell identification function may be useful as a clinical measure for the assessment of 
the clinical response to donepezil, as the entorhinal cortex, the olfactory bulb, critical areas 
for smell, are high in acecoline, a neurotransmitter involved in the pathology of Alzheimer’s 
disease and treatment.  
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